Get started
Author

Valérie Haine

Observed names: Haine, Valérie, Valerie Haine
Observed institution: GlaxoSmithKline (Belgium)
OpenAlex ID: A5012612629
Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
2022 · Nicolas Praet, Kwaku Poku Asante, et al. · Malaria Journal · 39
PDF
Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi
2025 · Latif Ndeketa, Valérie Haine, et al. · The Lancet Global Health · 12
Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study
2025 · Valérie Haine, Martina Oneko, et al. · The Lancet Global Health · 8
Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022
2025 · Kwaku Poku Asante, Marie-Cécile Bozonnat, et al. · The Lancet Global Health · 4
Correction to: Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine
2021 · Valérie Haine, The RTS,S Epidemiology EPI-MAL-002 Study Group · Malaria Journal · 1
PDF
Enhancing Disease Surveillance and Pharmacovigilance Practices for RTS,S/AS01E Malaria Vaccine Rollout in Ghana, Kenya, and Malawi: Strategies, Impact, Challenges, and Lessons Learned
2026 · Valérie Haine, Tene-Alima Essoh, et al. · Drug Safety
PDF
Works count: 7
Citation count: 64
H-index: 4
I10-index: 2
Year
Topic
Type